Latest news with #RheumatoidArthritis
Business Wire
3 days ago
- Business
- Business Wire
Sonoma Biotherapeutics Announces Poster Presentation at the 2025 European Alliance of Associations for Rheumatology (EULAR) Congress
SOUTH SAN FRANCISCO, Calif. & SEATTLE--(BUSINESS WIRE)-- Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, will be sharing a poster presentation at the 2025 European Alliance of Associations for Rheumatology (EULAR) Congress, taking place in Barcelona on June 11-14, 2025. Details of the presentations are as follows: Poster Presentation Details: Title: 'REGULATE-RA: A Phase 1 Study of CAR-Treg Cells Targeting Citrullinated Proteins in Refractory Rheumatoid Arthritis: Interim Report of Patient Characteristics and Safety' Presenting Author: Sarah K. Baxter, MD, PhD Poster number: POS0034 Session: Clinical Poster Tours: Difficult to treat Rheumatoid Arthritis Date/ Time: Location: Poster Tour IV About Sonoma Biotherapeutics Sonoma Biotherapeutics is a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases by restoring balance to the immune system. Founded by pioneers in Treg biology and cell therapy, the company is employing proprietary platform technologies and approaches to develop a new generation of targeted and durable Treg cell therapies. Sonoma Biotherapeutics is based in South San Francisco and Seattle. For more information, visit and follow on X, formerly Twitter, and LinkedIn.
Globe and Mail
20-05-2025
- Health
- Globe and Mail
Rheumatoid Arthritis Drugs Market 2034: Clinical Trials, Epidemiology, EMA, PDMA, FDA Approval, Revenue, Statistics, NICE Approvals, Therapies, and Companies by DelveInsight
"Rheumatoid Arthritis Drugs Market" Rheumatoid Arthritis Companies are Eli Lilly and Company, UCB BIOSCIENCES GmbH, Regeneron/Sanofi, AbbVie, Pfizer, Changchun GeneScience Pharma, Novartis, Istituto Giannina Gaslini, and others. (Albany, USA) DelveInsight's ' Rheumatoid Arthritis Market Insights, Epidemiology, and Market Forecast – 2034 ' report delivers an in-depth understanding of rheumatoid arthritis, historical and forecasted epidemiology as well as the Rheumatoid arthritis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. The Rheumatoid Arthritis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Rheumatoid Arthritis market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Rheumatoid Arthritis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Rheumatoid Arthritis market. Key Takeaways from the Rheumatoid Arthritis Market Report According to DelveInsight, Rheumatoid Arthritis Market Size in the 7MM was estimated to be around USD 29,000 million in 2023, which is expected to grow during the forecast period (2024–2034). Among the 7MM, the US accounted for the highest prevalent cases of rheumatoid arthritis in 2023, with around 1,430,000 cases were diagnosed with rheumatoid arthritis. Moreover, these cases are expected to increase during the forecast period. Amongst EU4 and the UK, the diagnosed prevalent cases of rheumatoid arthritis were highest in Germany, while the lowest number of cases was in France in 2023. In the US, the total age-specific prevalent cases of rheumatoid arthritis were highest in the age group for 55-64 years in 2023. The leading Rheumatoid Arthritis Companies such as Regeneron/Sanofi, Eli Lilly and Company, UCB BIOSCIENCES GmbH, AbbVie, Pfizer, Changchun GeneScience Pharma, Novartis, Istituto Giannina Gaslini, and others. Promising Rheumatoid Arthritis Therapies such as Sarilumab (Kevzara), Baricitinib, Certolizumab pegol, Upadacitinib, Tofacitinib, Sarilumab SAR153191 (REGN88), GenaKumab, AIN457, Etanercept, and others. In February 2025, Inmedix® introduced its CloudHRV™ System to U.S. rheumatologists during the Rheumatology Winter Clinical Symposium held in Wailea, Maui. Cleared for commercialization by the U.S. FDA on January 17, 2025, the CloudHRV System is a heart rate variability (HRV) diagnostic tool intended for clinical use at the discretion of healthcare providers. In February 2025, Zydus Lifesciences received final approval from the U.S. FDA to manufacture Ibuprofen and Famotidine tablets (800 mg/26.6 mg), marketed under the brand name Duexis. This combination therapy is prescribed for the relief of rheumatoid arthritis and osteoarthritis symptoms while also reducing the risk of upper gastrointestinal ulcers associated with long-term ibuprofen use. In January 2025, Celltrion, a prominent South Korean biopharmaceutical firm, announced U.S. FDA approval for its biosimilar Avtozma. Developed as a biosimilar to Actemra, Avtozma is available in both intravenous and subcutaneous forms and is indicated for autoimmune conditions such as rheumatoid arthritis, giant cell arteritis, and COVID-19. Additionally, in January 2025, Rise Therapeutics reported that the FDA accepted its Investigational New Drug (IND) application for a Phase 1 oncology trial of R-5780. The company continues to develop treatments targeting ulcerative colitis, rheumatoid arthritis, and type 1 diabetes. In September 2024, Celltrion announced FDA approval for a Phase 3 clinical study of Zymfentra (CT-P13 SC, infliximab), its subcutaneous Remicade biosimilar, for rheumatoid arthritis treatment. June 2024:- AbbVie- A Phase 3b/4 Randomized, Double-Blind, Double Dummy, Active Comparator-Controlled Study, Comparing the Efficacy and Safety of Upadacitinib Versus Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis on a Stable Background of MTX and Who Had an Inadequate Response or Intolerance to a Single TNF Inhibitor (SELECT- SWITCH). Rheumatoid Arthritis Overview Rheumatoid Arthritis is a chronic autoimmune disorder that primarily affects the joints, leading to inflammation, pain, and potential joint deformity. Rheumatoid Arthritis occurs when the immune system mistakenly attacks the synovium—the lining of the membranes that surround the joints. Rheumatoid Arthritis symptoms typically include joint stiffness, swelling, fatigue, and reduced range of motion, often affecting the wrists, hands, and knees symmetrically. Rheumatoid Arthritis diagnosis involves a combination of physical examinations, blood tests for inflammatory markers, and imaging techniques such as X-rays or MRIs to assess joint damage. Rheumatoid Arthritis progression can vary widely, with some individuals experiencing mild symptoms and others facing significant disability if left untreated Rheumatoid Arthritis treatment focuses on controlling inflammation and slowing disease progression through medications such as Disease-Modifying Anti-Rheumatic Drugs (DMARDs), biologics, and corticosteroids. Rheumatoid Arthritis management may also include lifestyle changes, physical therapy, and in severe cases, surgical intervention. Rheumatoid Arthritis research continues to advance, aiming for more targeted therapies and earlier diagnosis. Rheumatoid Arthritis awareness is essential for early detection and intervention, which can significantly improve long-term outcomes. Rheumatoid Arthritis patients benefit from a multidisciplinary approach involving rheumatologists, physical therapists, and support groups to enhance quality of life and manage daily challenges. Learn more about Rheumatoid Arthritis treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Rheumatoid Arthritis Treatment Market Rheumatoid Arthritis Epidemiology The Rheumatoid Arthritis epidemiology section provides insights into the historical and current Rheumatoid Arthritis patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Rheumatoid Arthritis market report also provides the diagnosed patient pool, trends, and assumptions. Rheumatoid Arthritis Epidemiology Segmentation: Total Prevalence of Rheumatoid Arthritis Prevalent Cases of Rheumatoid Arthritis by severity Gender-specific Prevalence of Rheumatoid Arthritis Diagnosed Cases of Episodic and Chronic Rheumatoid Arthritis Download the report to understand which factors are driving Rheumatoid Arthritis Epidemiology trends @ Rheumatoid Arthritis Prevalence Rheumatoid Arthritis Marketed Drugs • OLUMIANT (barticinib): Eli Lilly and Company/Incyte Corporation OLUMIANT is an immunosuppressant that is indicated for use in inflammatory and autoimmune diseases, or in other terms, it is defined as a Janus kinase (JAK) inhibitor used to treat adults with moderate to severe RA who have not responded well enough to or could not tolerate at least one medicine called a tumor necrosis factor (TNF) antagonist. This novel agent achieved its approval on the basis of well-conducted late-stage clinical trials in countries like the US, Europe, and Japan. OLUMIANT is approved with a Boxed Warning for the risk of serious infections, malignancies, and thrombosis. Currently, OLUMIANT is conducting a Phase II trial (NCT04870203) in combination with adalimumab in rheumatoid arthritis • RINVOQ (upadacitinib): AbbVie RINVOQ- an AbbVie product is a prescription medicine used to treat adults with moderate to severe RA in whom methotrexate did not work well or could not be tolerated. In August 2019, AbbVie announced that the US FDA has approved RINVOQ for the treatment of adults with moderately to severely active RA who have had an inadequate response or intolerance to methotrexate. Rheumatoid Arthritis Emerging Drugs • Rabeximod (Rob 803): Cyxone Rabeximod is an orally available drug with a unique mechanism of action that selectively targets the inflammatory macrophage, a type of white blood cell that is the central orchestrator of the inflammatory process that causes tissue destruction and clinical symptoms in rheumatoid arthritis. Rabeximod has been extensively studied in Phase I and Phase II clinical trials. Safety studies reveal a favorable safety profile compared to anti-rheumatoid arthritis drugs such as anti-TNFα monoclonal antibodies and oral JAK inhibitors. In June 2022, Cyxone received a response from a Type B pre-IND meeting with the US FDA. The response from the FDA facilitates for Cyxone to continue planning the Phase IIb study with Rabeximod in rheumatoid arthritis. • Imvotamab: IGM Biosciences Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. It has 10 binding units for CD20, and it may successfully bind to CD20 expressing B cells with more power (avidity) compared to an IgG bispecific antibody with only one or two binding units for CD20. The company is currently evaluating Imvotamab in Phase-Ib trial for severe rheumatoid arthritis and mostly autoimmune diseases mediated by B-cells. Additionally, in vitro studies show that Imvotamab is significantly more effective than rituximab in depleting low CD20 expressing cells. Rheumatoid Arthritis Market Outlook Rheumatoid Arthritis aims to control pain and inflammation and, ultimately, the goal is remission or at least low disease activity. The FDA that can slow the course of the disease and improve the quality of life has approved scarcely any drugs. Therefore, the management of rheumatoid arthritis remains supportive and symptom-based. In recent years, research on new treatment strategies has increased, taking heed of monoclonal antibodies, small molecules, and others. There are limited approved drugs that slow disease progression by prolonging autonomy and increasing survival rates. Moreover, approved by the US FDA to treat rheumatoid arthritis, including OLUMIANT, RINVOQ, and ORENCIA. Rheumatoid Arthritis Drug Market The pipeline holds multiple promising therapies in various stages of development, most of which are vaccines. Therapies like Rabeximod (Cyxon), Imvotamab (IGM Biosciences), and others are the drugs and Monoclonal antibodies currently in Phase II and Ib trials focusing on Macrophage inhibition and CD cells depletion, and more may follow in the future. The current pipeline does not hold great potential as most of the products are currently in initial and mid stage trials and most of the drugs failed in their last stage trials as the studies did not meet primary and secondary efficacy endpoints in rheumatoid arthritis treatment. However, Rabeximod by Cyxone is a new drug candidate and unique among marketed drugs as well as drugs in development as it selectively targets rheumatoid arthritis via the NFkB pathway of inflammatory macrophages, the central orchestrators of the inflammatory process responsible for tissue destruction and clinical symptoms in rheumatoid arthritis. Scope of the Rheumatoid Arthritis Market Report Coverage- 7MM Rheumatoid Arthritis Companies- Major pharmaceutical and biotechnology companies such as Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Sanofi (EPA: SAN), Eli Lilly and Company (NYSE: LLY), UCB BIOSCIENCES GmbH (part of UCB S.A., EBR: UCB), AbbVie Inc. (NYSE: ABBV), Pfizer Inc. (NYSE: PFE), Changchun GeneScience Pharma (SHE: 000661), Novartis (SWX: NOVN), Istituto Giannina Gaslini, and others. Rheumatoid Arthritis Therapies- Sarilumab (Kevzara), Baricitinib, Certolizumab pegol, Upadacitinib, Tofacitinib, Sarilumab SAR153191 (REGN88), GenaKumab, AIN457, Etanercept, and others. Rheumatoid Arthritis Market Dynamics: Rheumatoid Arthritis Market Drivers and Barriers Rheumatoid Arthritis Market Access and Reimbursement, Unmet Needs and Future Perspectives Discover more about Rheumatoid Arthritis Drugs in development @ Rheumatoid Arthritis Clinical Trials Assessment and Pipeline Analysis Table of Content 1 Key Insights 2 Report Introduction 3 Executive Summary 4 Key Events 5 Epidemiology and Market Forecast Flow Methodology 6 Rheumatoid Arthritis Market Overview at a Glance 7 Disease Background and Overview 8 Treatment and Management of Rheumatoid Arthritis 9 Guidelines for Management of Rheumatoid Arthritis with Synthetic and Biological Disease-modifying Antirheumatic Drugs (European Alliance of Associations for Rheumatology) 10 Treatment Guidelines for RA (National Institute for Health and Care Excellence) 11 Guidelines for Management of RA (American College of Rheumatology) 12 Clinical Practice Guidelines for RA (Italian Society for Rheumatology) 13 Guidelines for the use of methotrexate in patients with Rheumatoid Arthritis (Japan College of Rheumatology (JCR)) 14 Treatment Algorithm 15 Epidemiology and Patient Population of 7MM 16 Patient Journey 17 Key Endpoints in Rheumatoid Arthritis Clinical Trials 18 Marketed Drugs 19 Emerging Drugs 20 Rheumatoid arthritis: 7MM Market Analysis 21 Unmet Needs 22 SWOT Analysis 23 Market Access and Reimbursement of Rheumatoid Arthritis Therapies 24 KOL Views 25 Appendix 26 DelveInsight Capabilities 27 Disclaimer 28 About DelveInsight About DelveInsight DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website:
Medscape
07-05-2025
- Health
- Medscape
Is Carpal Tunnel an Early Sign of Rheumatoid Arthritis?
TOPLINE: Carpal tunnel syndrome (CTS) appeared more than twice as frequently in patients before rheumatoid arthritis (RA) diagnosis than in those without RA, suggesting that CTS could serve as an early indicator for RA risk. METHODOLOGY: Researchers conducted a population-based study using the Rochester Epidemiology Project, which provides comprehensive longitudinal health information from Olmsted County, Minnesota. Analysis included 1335 patients with RA meeting the 1987 American College of Rheumatology classification criteria between 1980 and 2019. Patients with RA were matched 1:1 with 1331 control individuals. Investigators identified CTS cases through two or more diagnosis codes occurring at least 30 days apart. TAKEAWAY: A total of 13% of individuals who developed RA were diagnosed with CTS prior to or at the onset of RA compared with 6% in non-RA individuals (odds ratio [OR], 2.23; 95% CI, 1.69-2.94). In patients with RA, most CTS diagnoses occurred at least 2 years before the onset of RA. Patients with RA were also at an increased risk for CTS following the onset of RA (hazard ratio [HR], 1.78; 95% CI, 1.38-2.30). Obesity (HR, 1.42; 95% CI, 1.02-1.99) and seronegativity for anti–cyclic citrullinated peptide antibodies (HR, 1.79; 95% CI, 1.07-2.99) were associated with increased risk for CTS in the RA group. IN PRACTICE: 'Increased vigilance is needed in individuals with CTS regarding the risk of developing RA. Referral to a rheumatologist can be considered, particularly in persistent and severe forms of CTS (eg, patients requiring carpal tunnel release surgery), that are not otherwise explained by traditional risk factors (eg, obesity, hypothyroidism, [diabetes mellitus]) and regardless of serostatus,' wrote the authors of the study. SOURCE: This study was led by Roslin Jose George, MBBS, MPH, of the Mayo Clinic in Rochester, Minnesota. It was published online in Arthritis Care & Research on May 5, 2025. LIMITATIONS: This study population was predominantly White from Olmsted County and surrounding areas in Minnesota, potentially limiting generalizability to more diverse populations. The researchers used code-based definitions for CTS ascertainment, which may have introduced healthcare utilization bias as patients with milder CTS might not seek medical care. Additionally, information about unilateral vs bilateral CTS and detailed joint count scores was not collected during the record review, which could have provided better understanding of CTS severity and its association with RA. DISCLOSURES: This study received funding from grants provided by the National Institutes of Health, National Institute of Arthritis, Musculoskeletal and Skin Diseases, and National Institute on Aging. The Rochester Epidemiology Project medical records-linkage system was supported by the National Institute on Aging, Mayo Clinic Research Committee, and user fees. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Scoop
29-04-2025
- Health
- Scoop
World-First Immunotherapy Trial To Treat Type 1 Diabetes
Researchers at The University of Queensland have dosed 5 participants in the first clinical trial of a potentially revolutionary immunotherapy drug to treat Type 1 diabetes. Professor Ranjeny Thomas AM from UQ's Frazer Institute has led the development of a targeted immunotherapy drug, ASITI-201, which has been designed to rebalance the body's immune response to protect insulin-producing pancreatic cells. 'In people with Type 1 diabetes, the immune system starts to recognise pancreatic cells as something it needs to attack, and right now the only available treatment is insulin replacement,' Professor Thomas said. 'We've taken a new approach and developed ASITI-201 using a protein from the pancreas, along with vitamin D to calm the immune response. 'This potential treatment uses the immune system's ability to heal and has been successful in controlling the disease in mice.' Lead investigator Dr Aakansha Zala said the drug candidate aims to preserve as much pancreatic function for as long as possible in people recently diagnosed with Type 1 diabetes, to reduce the amount of insulin they need to administer. 'We are looking for people over the age of 18 who have been diagnosed with Type 1 diabetes within the last 5 years, to participate in the trial at the Translational Research Institute's Clinical Research Facility based at Brisbane's Princess Alexandra Hospital,' Dr Zala said. 'We will be looking at whether the drug changes the immune system in the way that we anticipate.' Type 1 diabetes affects more than 120,000 Australians and usually develops in children and young adults. 'Ultimately, we need to move to larger trials which include children, who have a much faster progression to insulin dependence,' Professor Thomas said. 'We've been developing a similar drug with the potential to treat Rheumatoid Arthritis, and that knowledge has supported our development of this drug for Type 1 diabetes.' The trial itself is being funded by the Medical Research Future Fund via Australia's national biotech incubator CUREator which helped form spin-out company Liperate Therapeutics – which was established by UQ's commercialisation company UniQuest. The drug's preclinical proof of concept was supported by multiple grants from Breakthrough T1D (formerly JDRF) totalling $2.54 million between 2003-2015. The Leona M. and Harry B. Helmsley Charitable Trust subsequently awarded two grants totalling $5.33 million to complete the preclinical development of the drug candidate, including safety studies and manufacturing. Dr Ben Williams, Program Officer at Helmsley Charitable Trust, said the organisation is proud to have supported the research which is a step towards improving the lives of people with Type 1 diabetes. 'Bringing drug candidates from the laboratory into clinical testing is always a herculean effort,' Dr Williams said. The Helmsley Charitable Trust is the largest private funder dedicated to transforming the trajectory of Type 1 diabetes.
Globe and Mail
15-04-2025
- Health
- Globe and Mail
Rheumatoid Arthritis Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Epidemiology, Revenue, Statistics, Therapies, and Companies by DelveInsight
"Rheumatoid Arthritis Treatment Market" Rheumatoid Arthritis Companies are Regeneron/Sanofi, Eli Lilly and Company, UCB BIOSCIENCES GmbH, AbbVie, Pfizer, Changchun GeneScience Pharma, Novartis, Istituto Giannina Gaslini, and others. (Albany, USA) DelveInsight's "Rheumatoid Arthritis Market Insights, Epidemiology, and Market Forecast – 2034" report delivers an in-depth understanding of rheumatoid arthritis, historical and forecasted epidemiology as well as the Rheumatoid arthritis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. The Rheumatoid Arthritis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Rheumatoid Arthritis market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Rheumatoid Arthritis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Rheumatoid Arthritis market. Key Takeaways from the Rheumatoid Arthritis Market Report According to DelveInsight, Rheumatoid Arthritis Market Size in the 7MM was estimated to be around USD 29,000 million in 2023, which is expected to grow during the forecast period (2024–2034). Among the 7MM, the US accounted for the highest prevalent cases of rheumatoid arthritis in 2023, with around 1,430,000 cases were diagnosed with rheumatoid arthritis. Moreover, these cases are expected to increase during the forecast period. Amongst EU4 and the UK, the diagnosed prevalent cases of rheumatoid arthritis were highest in Germany, while the lowest number of cases was in France in 2023. In the US, the total age-specific prevalent cases of rheumatoid arthritis were highest in the age group for 55-64 years in 2023. The leading Rheumatoid Arthritis Companies such as Regeneron/Sanofi, Eli Lilly and Company, UCB BIOSCIENCES GmbH, AbbVie, Pfizer, Changchun GeneScience Pharma, Novartis, Istituto Giannina Gaslini, and others. Promising Rheumatoid Arthritis Therapies such as Sarilumab (Kevzara), Baricitinib, Certolizumab pegol, Upadacitinib, Tofacitinib, Sarilumab SAR153191 (REGN88), GenaKumab, AIN457, Etanercept, and others. In February 2025, Inmedix® introduced its CloudHRV™ System to U.S. rheumatologists during the Rheumatology Winter Clinical Symposium held in Wailea, Maui. Cleared for commercialization by the U.S. FDA on January 17, 2025, the CloudHRV System is a heart rate variability (HRV) diagnostic tool intended for clinical use at the discretion of healthcare providers. In February 2025, Zydus Lifesciences received final approval from the U.S. FDA to manufacture Ibuprofen and Famotidine tablets (800 mg/26.6 mg), marketed under the brand name Duexis. This combination therapy is prescribed for the relief of rheumatoid arthritis and osteoarthritis symptoms while also reducing the risk of upper gastrointestinal ulcers associated with long-term ibuprofen use. In January 2025, Celltrion, a prominent South Korean biopharmaceutical firm, announced U.S. FDA approval for its biosimilar Avtozma. Developed as a biosimilar to Actemra, Avtozma is available in both intravenous and subcutaneous forms and is indicated for autoimmune conditions such as rheumatoid arthritis, giant cell arteritis, and COVID-19. Additionally, in January 2025, Rise Therapeutics reported that the FDA accepted its Investigational New Drug (IND) application for a Phase 1 oncology trial of R-5780. The company continues to develop treatments targeting ulcerative colitis, rheumatoid arthritis, and type 1 diabetes. In September 2024, Celltrion announced FDA approval for a Phase 3 clinical study of Zymfentra (CT-P13 SC, infliximab), its subcutaneous Remicade biosimilar, for rheumatoid arthritis treatment. June 2024:- AbbVie- A Phase 3b/4 Randomized, Double-Blind, Double Dummy, Active Comparator-Controlled Study, Comparing the Efficacy and Safety of Upadacitinib Versus Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis on a Stable Background of MTX and Who Had an Inadequate Response or Intolerance to a Single TNF Inhibitor (SELECT- SWITCH). Rheumatoid Arthritis Overview Rheumatoid Arthritis is a chronic autoimmune disorder that primarily affects the joints, leading to inflammation, pain, and potential joint deformity. Rheumatoid Arthritis occurs when the immune system mistakenly attacks the synovium—the lining of the membranes that surround the joints. Rheumatoid Arthritis symptoms typically include joint stiffness, swelling, fatigue, and reduced range of motion, often affecting the wrists, hands, and knees symmetrically. Rheumatoid Arthritis diagnosis involves a combination of physical examinations, blood tests for inflammatory markers, and imaging techniques such as X-rays or MRIs to assess joint damage. Rheumatoid Arthritis progression can vary widely, with some individuals experiencing mild symptoms and others facing significant disability if left untreated Rheumatoid Arthritis treatment focuses on controlling inflammation and slowing disease progression through medications such as Disease-Modifying Anti-Rheumatic Drugs (DMARDs), biologics, and corticosteroids. Rheumatoid Arthritis management may also include lifestyle changes, physical therapy, and in severe cases, surgical intervention. Rheumatoid Arthritis research continues to advance, aiming for more targeted therapies and earlier diagnosis. Rheumatoid Arthritis awareness is essential for early detection and intervention, which can significantly improve long-term outcomes. Rheumatoid Arthritis patients benefit from a multidisciplinary approach involving rheumatologists, physical therapists, and support groups to enhance quality of life and manage daily challenges. Learn more about Rheumatoid Arthritis treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Rheumatoid Arthritis Treatment Market Rheumatoid Arthritis Epidemiology The Rheumatoid Arthritis epidemiology section provides insights into the historical and current Rheumatoid Arthritis patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Rheumatoid Arthritis market report also provides the diagnosed patient pool, trends, and assumptions. Rheumatoid Arthritis Epidemiology Segmentation: Download the report to understand which factors are driving Rheumatoid Arthritis Epidemiology trends @ Rheumatoid Arthritis Prevalence Rheumatoid Arthritis Marketed Drugs • OLUMIANT (barticinib): Eli Lilly and Company/Incyte Corporation OLUMIANT is an immunosuppressant that is indicated for use in inflammatory and autoimmune diseases, or in other terms, it is defined as a Janus kinase (JAK) inhibitor used to treat adults with moderate to severe RA who have not responded well enough to or could not tolerate at least one medicine called a tumor necrosis factor (TNF) antagonist. This novel agent achieved its approval on the basis of well-conducted late-stage clinical trials in countries like the US, Europe, and Japan. OLUMIANT is approved with a Boxed Warning for the risk of serious infections, malignancies, and thrombosis. Currently, OLUMIANT is conducting a Phase II trial (NCT04870203) in combination with adalimumab in rheumatoid arthritis • RINVOQ (upadacitinib): AbbVie RINVOQ- an AbbVie product is a prescription medicine used to treat adults with moderate to severe RA in whom methotrexate did not work well or could not be tolerated. In August 2019, AbbVie announced that the US FDA has approved RINVOQ for the treatment of adults with moderately to severely active RA who have had an inadequate response or intolerance to methotrexate. Rheumatoid Arthritis Emerging Drugs • Rabeximod (Rob 803): Cyxone Rabeximod is an orally available drug with a unique mechanism of action that selectively targets the inflammatory macrophage, a type of white blood cell that is the central orchestrator of the inflammatory process that causes tissue destruction and clinical symptoms in rheumatoid arthritis. Rabeximod has been extensively studied in Phase I and Phase II clinical trials. Safety studies reveal a favorable safety profile compared to anti-rheumatoid arthritis drugs such as anti-TNFα monoclonal antibodies and oral JAK inhibitors. In June 2022, Cyxone received a response from a Type B pre-IND meeting with the US FDA. The response from the FDA facilitates for Cyxone to continue planning the Phase IIb study with Rabeximod in rheumatoid arthritis. • Imvotamab: IGM Biosciences Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. It has 10 binding units for CD20, and it may successfully bind to CD20 expressing B cells with more power (avidity) compared to an IgG bispecific antibody with only one or two binding units for CD20. The company is currently evaluating Imvotamab in Phase-Ib trial for severe rheumatoid arthritis and mostly autoimmune diseases mediated by B-cells. Additionally, in vitro studies show that Imvotamab is significantly more effective than rituximab in depleting low CD20 expressing cells. Rheumatoid Arthritis Market Outlook Rheumatoid Arthritis aims to control pain and inflammation and, ultimately, the goal is remission or at least low disease activity. The FDA that can slow the course of the disease and improve the quality of life has approved scarcely any drugs. Therefore, the management of rheumatoid arthritis remains supportive and symptom-based. In recent years, research on new treatment strategies has increased, taking heed of monoclonal antibodies, small molecules, and others. There are limited approved drugs that slow disease progression by prolonging autonomy and increasing survival rates. Moreover, approved by the US FDA to treat rheumatoid arthritis, including OLUMIANT, RINVOQ, and ORENCIA. Rheumatoid Arthritis Drug Market The pipeline holds multiple promising therapies in various stages of development, most of which are vaccines. Therapies like Rabeximod (Cyxon), Imvotamab (IGM Biosciences), and others are the drugs and Monoclonal antibodies currently in Phase II and Ib trials focusing on Macrophage inhibition and CD cells depletion, and more may follow in the future. The current pipeline does not hold great potential as most of the products are currently in initial and mid stage trials and most of the drugs failed in their last stage trials as the studies did not meet primary and secondary efficacy endpoints in rheumatoid arthritis treatment. However, Rabeximod by Cyxone is a new drug candidate and unique among marketed drugs as well as drugs in development as it selectively targets rheumatoid arthritis via the NFkB pathway of inflammatory macrophages, the central orchestrators of the inflammatory process responsible for tissue destruction and clinical symptoms in rheumatoid arthritis. Scope of the Rheumatoid Arthritis Market Report Coverage- 7MM Rheumatoid Arthritis Companies- Major pharmaceutical and biotechnology companies such as Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Sanofi (EPA: SAN), Eli Lilly and Company (NYSE: LLY), UCB BIOSCIENCES GmbH (part of UCB S.A., EBR: UCB), AbbVie Inc. (NYSE: ABBV), Pfizer Inc. (NYSE: PFE), Changchun GeneScience Pharma (SHE: 000661), Novartis (SWX: NOVN), Istituto Giannina Gaslini, and others. Rheumatoid Arthritis Therapies- Sarilumab (Kevzara), Baricitinib, Certolizumab pegol, Upadacitinib, Tofacitinib, Sarilumab SAR153191 (REGN88), GenaKumab, AIN457, Etanercept, and others. Rheumatoid Arthritis Market Dynamics: Rheumatoid Arthritis Market Drivers and Barriers Rheumatoid Arthritis Market Access and Reimbursement, Unmet Needs and Future Perspectives Discover more about Rheumatoid Arthritis Drugs in development @ Rheumatoid Arthritis Clinical Trials Assessment and Pipeline Analysis Table of Content 1 Key Insights 2 Report Introduction 3 Executive Summary 4 Key Events 5 Epidemiology and Market Forecast Flow Methodology 6 Rheumatoid Arthritis Market Overview at a Glance 7 Disease Background and Overview 8 Treatment and Management of Rheumatoid Arthritis 9 Guidelines for Management of Rheumatoid Arthritis with Synthetic and Biological Disease-modifying Antirheumatic Drugs (European Alliance of Associations for Rheumatology) 10 Treatment Guidelines for RA (National Institute for Health and Care Excellence) 11 Guidelines for Management of RA (American College of Rheumatology) 12 Clinical Practice Guidelines for RA (Italian Society for Rheumatology) 13 Guidelines for the use of methotrexate in patients with Rheumatoid Arthritis (Japan College of Rheumatology (JCR)) 14 Treatment Algorithm 15 Epidemiology and Patient Population of 7MM 16 Patient Journey 17 Key Endpoints in Rheumatoid Arthritis Clinical Trials 18 Marketed Drugs 19 Emerging Drugs 20 Rheumatoid arthritis: 7MM Market Analysis 21 Unmet Needs 22 SWOT Analysis 23 Market Access and Reimbursement of Rheumatoid Arthritis Therapies 24 KOL Views 25 Appendix 26 DelveInsight Capabilities 27 Disclaimer 28 About DelveInsight About DelveInsight DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website:
